Belle-Isle L, Hathaway A
Canadian AIDS Society, Otawa, Ontario.
AIDS Care. 2007 Apr;19(4):500-6. doi: 10.1080/09540120701207833.
North American studies suggest that as many as one-third of people living with HIV/AIDS self-medicate with cannabis for relief of physical and stress-related symptoms. Although cannabis remains a controlled substance in Canada, legal access has been granted to people with HIV/AIDS and other serious illness under the Marihuana Medical Access Regulations (MMAR) since 2001. Several years into the programme, however, few Canadians ( approximately 1400) have obtained MMAR approval, suggesting that substantial obstacles remain. This paper reports findings from a 2005 survey (n=197) and focus groups conducted to identify barriers to access to medical cannabis among people living with HIV/AIDS. Most (86%) respondents who reported using cannabis as medicine continue to rely on illegal sources for their supply. They cited lack of information, product quality concerns, and an onerous, confusing application process among other problems mentioned with the MMAR. The findings are discussed in terms of policy suggestions for facilitating access to a legal source of cannabis for medical users.
北美研究表明，多达三分之一的艾滋病毒/艾滋病感染者自行使用大麻来缓解身体症状和与压力相关的症状。尽管大麻在加拿大仍是受管制物质，但自2001年以来，根据《医用大麻获取条例》（MMAR），艾滋病毒/艾滋病感染者及其他重症患者已被允许合法获取大麻。然而，该计划实施数年之后，获得MMAR批准的加拿大人寥寥无几（约1400人），这表明仍然存在重大障碍。本文报告了2005年一项调查（n = 197）的结果以及为确定艾滋病毒/艾滋病感染者获取医用大麻的障碍而开展的焦点小组讨论结果。大多数（86%）报告将大麻用作药物的受访者仍依赖非法渠道获取大麻。他们提到了信息匮乏、对产品质量的担忧以及MMAR存在的其他问题，如申请过程繁琐、令人困惑等。本文将根据促进医用大麻合法来源获取的政策建议对这些研究结果进行讨论。
